• Return to Headlines

Pdl Biopharma In is Among the Companies in the Biotechnology Industry With the Lowest EBITDA Growth (PDLI, UTHR, GILD, MYGN, AMGN)

By James Quinn

Below are the three companies in the Biotechnology industry with the lowest EBITDA Growth (next year estimate vs. LTM). EBITDA Growth can be valuable in predicting future cash flow generation and earnings power.

Pdl Biopharma In ranks lowest with a EBITDA growth of -63.9%. United Therapeut is next with a EBITDA growth of -37.2%. Gilead Sciences ranks third lowest with a EBITDA growth of -13.7%.

Myriad Genetics follows with a EBITDA growth of -12.2%, and Amgen Inc rounds out the bottom five with a EBITDA growth of 6.6%.

SmarTrend recommended that subscribers consider buying shares of Amgen Inc on May 22nd, 2018 as our technology indicated a new Uptrend was in progress when shares hit $178.04. Since that recommendation, shares of Amgen Inc have risen 9.2%. We continue to monitor Amgen Inc for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Keywords: lowest ebitda growth pdl biopharma in united therapeut Gilead Sciences myriad genetics amgen inc

Ticker(s): PDLI UTHR GILD MYGN AMGN